Literature DB >> 24549319

High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit.

Michael J Hassett1, Kristen K McNiff2, Adam P Dicker2, Timothy Gilligan2, Carolyn B Hendricks2, Inga Lennes2, Thomas Murray2, Monika K Krzyzanowska2.   

Abstract

PURPOSE: Most cancer quality measures focus on individual cancers, assess specific providers, and evaluate processes of care. Although important, these efforts are not sufficient. A more comprehensive measure set is needed to address gaps in care, focus on patients rather than providers, and assess the cross-cutting aspects of care that are relevant to all patients with cancer throughout the trajectory of their illness.
METHODS: With the long-term goal of developing a more comprehensive oncology measure set, the American Society of Clinical Oncology (ASCO) organized a collaborative measure summit that used an iterative consensus approach to identify priorities for the development of new cancer quality measures. The summit, which included professional societies and patient/consumer advocacy organizations, was held during the ASCO Quality Care Symposium in December 2012.
RESULTS: This effort, which brought together 12 diverse stakeholders, identified 10 high-priority topics for cancer quality measure development that cross-cut cancer diagnoses and care settings and addressed patient-centered concerns. Topics of particular interest included planning and counseling before therapy, interdisciplinary and multidisciplinary coordinated care, comprehensive symptom assessment, patient experience of care, and use of palliative care and hospice services.
CONCLUSION: This is an important first step in the development of patient-centered, cross-cutting cancer quality measures. Addressing the high-priority topics identified by this effort will help fill the gaps left by existing cancer quality measures, including care coordination and transitions, quality of life, safety, experience of care, and outcomes. More work will be needed to specify, implement, and validate measures based on these topics.
Copyright © 2014 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2014        PMID: 24549319     DOI: 10.1200/JOP.2013.001240

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  6 in total

1.  Nurturing Advocacy Inclusion to Bring Health Equity in Breast Cancer among African American Women.

Authors:  Kimlin Tam Ashing; Aria M Miller; Eudora Mitchell; Virginia Martin; Kommah McDowell; Rhonda Santifer; June Smith; Shirley Brown; Camille Ragin; Agatha Carrington
Journal:  Breast Cancer Manag       Date:  2014

Review 2.  Quality measures for palliative care in patients with cancer: a systematic review.

Authors:  Arif H Kamal; Margaret Gradison; Jennifer M Maguire; Donald Taylor; Amy P Abernethy
Journal:  J Oncol Pract       Date:  2014-06-10       Impact factor: 3.840

3.  A Clinical Decision Support System for Monitoring Post-Colonoscopy Patient Follow-Up and Scheduling.

Authors:  Roxanne Wadia; Mark Shifman; Forrest L Levin; Luis Marenco; Cynthia A Brandt; Kei-Hoi Cheung; Tamar Taddei; Michael Krauthammer
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2017-07-26

4.  Charting a path to high-quality end-of-life care for children with cancer.

Authors:  Prasanna Ananth; Joanne Wolfe; Emily E Johnston
Journal:  Cancer       Date:  2022-08-25       Impact factor: 6.921

5.  A Stakeholder-Driven Qualitative Study to Define High Quality End-of-Life Care for Children With Cancer.

Authors:  Prasanna Ananth; Sophia Mun; Noora Reffat; Randall Li; Tannaz Sedghi; Madeline Avery; Jennifer Snaman; Cary P Gross; Xiaomei Ma; Joanne Wolfe
Journal:  J Pain Symptom Manage       Date:  2021-02-05       Impact factor: 5.576

6.  Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma.

Authors:  Robert Chen; Suzanne Allibone; Nancy L Bartlett; Pauline Brice; Andy Chen; Katrina Pose; Lynn Rich; Vijay Bonthapally; Phillip M Garfin; Michelle Fanale
Journal:  Onco Targets Ther       Date:  2016-04-06       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.